Volume 11 Issue 2
Mar.  2020
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2020  >  11(2): 298-303
Yang Jian, Xie Yan, Tian Dazhi, et al. Research progress on molecular mechanism of hepatitis B virus reactivation after liver transplantation[J]. ORGAN TRANSPLANTATION, 2020, 11(2): 298-303. doi: 10.3969/j.issn.1674-7445.2020.02.019
Citation: Yang Jian, Xie Yan, Tian Dazhi, et al. Research progress on molecular mechanism of hepatitis B virus reactivation after liver transplantation[J]. ORGAN TRANSPLANTATION, 2020, 11(2): 298-303. doi: 10.3969/j.issn.1674-7445.2020.02.019
shu

Research progress on molecular mechanism of hepatitis B virus reactivation after liver transplantation

doi: 10.3969/j.issn.1674-7445.2020.02.019

  • Organ Transplantation Center, Department of Organ Transplantation, Tianjin First Central Hospital, Tianjin 300192, China

More Information
  • Corresponding author: Jiang Wentao, Email: 447660280@qq.com
  • Received Date: 2019-12-20
    Available Online: 2021-01-19
  • Publish Date: 2020-03-15
    Abstract
  • Liver transplantation is the most effective method for hepatitis B-related liver failure, liver cirrhosis and hepatocellular carcinoma. However, the reactivation of hepatitis B virus (HBV) after liver transplantation is not conducive to the recovery of liver function and leads to poor clinical prognosis. The prevention and treatment of HBV reactivation is currently the focus of research by physicians and surgeons. The current viral suppression strategies can not completely eradicate HBV nor completely prevent the recurrence of HBV infection in the future. This article aims to explore the molecular mechanism of HBV reactivation after liver transplantation, in order to more effectively prevent the recurrence of hepatitis B after liver transplantation.

     

    • FullText(HTML)
  • loading
    • References(43)
  • [1]
    STOCKDALE AJ, MITAMBO C, EVERETT D, et al. Epidemiology of hepatitis B, C and D in Malawi: systematic review[J]. BMC Infect Dis, 2018, 18(1):516. DOI: 10.1186/s12879-018-3428-7.
    [2]
    HIBI T, SUGAWARA Y. Locoregional therapy as a bridge to liver transplantation for hepatocellular carcinoma within Milan criteria: from a transplant oncology viewpoint[J]. Hepatobiliary Surg Nutr, 2018, 7(2):134-135. DOI: 10.21037/hbsn.2018.01.07.
    [3]
    BODZIN AS, BAKER TB. Liver transplantation today: where we are now and where we are going[J]. Liver Transpl, 2018, 24(10):1470-1475. DOI: 10.1002/lt.25320.
    [4]
    TAHARA H, OHDAN H. HBV reactivation after liver transplantation and the management strategies[J]. Nihon Rinsho, 2015, 73 (Suppl 9):550-554. http://cn.bing.com/academic/profile?id=d402e9ce2f5365994b57558ba5a85f2e&encoded=0&v=paper_preview&mkt=zh-cn
    [5]
    SORIANO V, BARREIRO P, BENITEZ L, et al. New antivirals for the treatment of chronic hepatitis B[J]. Expert Opin Investig Drugs, 2017, 26(7):843-851. DOI: 10.1080/13543784.2017.1333105.
    [6]
    MAIER M, LIEBERT UG, WITTEKIND C, et al. Clinical relevance of minimal residual viremia during long-term therapy with nucleos(t)ide analogues in patients with chronic hepatitis B[J]. PLoS One, 2013, 8(6):e67481. DOI: 10.1371/journal.pone.0067481.
    [7]
    LI X, ZHAO J, YUAN Q, et al. Detection of HBV covalently closed circular DNA[J]. Viruses, 2017, 9(6):139. DOI: 10.3390/v9060139.
    [8]
    KASRAIANFARD A, WATT KD, LINDBERG L, et al. HBIG remains significant in the era of new potent nucleoside analogues for prophylaxis against hepatitis B recurrence after liver transplantation[J]. Int Rev Immunol, 2016, 35(4):312-324. http://www.ncbi.nlm.nih.gov/pubmed/24911598
    [9]
    CHAUHAN R, LINGALA S, GADIPARTHI C, et al. Reactivation of hepatitis B after liver transplantation: current knowledge, molecular mechanisms and implications in management[J]. World J Hepatol, 2018, 10(3):352-370. DOI: 10.4254/wjh.v10.i3.352.
    [10]
    LIU S, ZHOU B, VALDES JD, et al. Serum hepatitis B virus RNA: a new potential biomarker for chronic hepatitis B virus infection[J]. Hepatology, 2019, 69(4):1816-1827. DOI: 10.1002/hep.30325.
    [11]
    WONG DK, SETO WK, FUNG J, et al. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency[J]. Clin Gastroenterol Hepatol, 2013, 11(8):1004-1010. DOI: 10.1016/j.cgh.2013.01.026.
    [12]
    PAPATHEODORIDIS GV, MANOLAKOPOULOS S, TOULOUMI G, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study[J]. Gut, 2011, 60(8):1109-1116. DOI: 10.1136/gut.2010.221846.
    [13]
    GENTILE G, ANDREONI M, ANTONELLI G, et al. Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: a systematic review[J]. Clin Microbiol Infect, 2017, 23(12):916-923. DOI: 10.1016/j.cmi.2017.06.024.
    [14]
    LIN CL, KAO JH. Natural history of acute and chronic hepatitis B: the role of HBV genotypes and mutants[J]. Best Pract Res Clin Gastroenterol, 2017, 31(3):249-255. DOI: 10.1016/j.bpg.2017.04.010.
    [15]
    ITO K, YONEDA M, SAKAMOTO K, et al. Virological and clinical characteristics of hepatitis B virus genotype A[J]. J Gastroenterol, 2018, 53(1):18-26. DOI: 10.1007/s00535-017-1367-5.
    [16]
    UZ-ZAMAN MH, RAHMAN A, YASMIN M. Epidemiology of hepatitis B virus infection in Bangladesh: prevalence among general population, risk groups and genotype distribution[J]. Genes (Basel), 2018, 9(11):541. DOI: 10.3390/genes9110541.
    [17]
    YEH CT, LIANG KH, CHANG ML, et al. Phenotypic and genotypic shifts in hepatitis B virus in treatment-naive patients, Taiwan, 2008-2012[J]. Emerg Infect Dis, 2017, 23(5):820-821. DOI: 10.3201/eid2305.161894.
    [18]
    HASSEMER M, FINKERNAGEL M, PEIFFER KH, et al. Comparative characterization of hepatitis B virus surface antigen derived from different hepatitis B virus genotypes[J]. Virology, 2017, 502:1-12. DOI: 10.1016/j.virol.2016.12.003.
    [19]
    LI X, LIU Y, XIN S, et al. Comparison of detection rate and mutational pattern of drug-resistant mutations between a large cohort of genotype B and genotype C hepatitis B virus-infected patients in north China[J]. Microb Drug Resist, 2017, 23(4):516-522. DOI: 10.1089/mdr.2016.0093.
    [20]
    GOYAL A, MURRAY JM. Roadmap to control HBV and HDV epidemics in China[J]. J Theor Biol, 2017, 423:41-52. DOI: 10.1016/j.jtbi.2017.04.007.
    [21]
    COUTO I, VICTORIA M, VELOSO VG, et al. Prevalence and predictors for compensated advanced chronic liver disease (c-ACLD) in patients with chronic hepatitis delta virus (HDV) infection[J]. PLoS One, 2017, 12(3):e0174453. DOI: 10.1371/journal.pone.0174453.
    [22]
    STROFFOLINI T, SAGNELLI E, SAGNELLI C, et al. Hepatitis delta infection in Italian patients: towards the end of the story?[J]. Infection, 2017, 45(3):277-281. DOI: 10.1007/s15010-016-0956-1.
    [23]
    RICCO G, POPA DC, CAVALLONE D, et al. Quantification of serum markers of hepatitis B (HBV) and Delta virus (HDV) infections in patients with chronic HDV infection[J]. J Viral Hepat, 2018, 25(8):911-919. DOI: 10.1111/jvh.12895.
    [24]
    LUPIA T, CORCIONE S, BOGLIONE L, et al. Visceral leishmaniasis in a patient with active HBV/HDV co-infection[J]. J Infect Public Health, 2020, 13(2):306-308. DOI: 10.1016/j.jiph.2019.07.026.
    [25]
    PEREZ-VARGAS J, AMIRACHE F, BOSON B, et al. Enveloped viruses distinct from HBV induce dissemination of hepatitis D virus in vivo[J]. Nat Commun, 2019, 10(1):2098. DOI: 10.1038/s41467-019-10117-z.
    [26]
    YURDAYDIN C, ABBAS Z, BUTI M, et al. Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy[J]. J Hepatol, 2019, 70(5):1008-1015. DOI: 10.1016/j.jhep.2018.12.022.
    [27]
    HÖNER ZU SIEDERDISSEN C, CORNBERG M. Management of HBV and HBV/HDV-associated liver cirrhosis[J]. Visc Med, 2016, 32(2):86-94. DOI: 10.1159/ 000445518.
    [28]
    JIANG Z, FENG X, ZHANG W, et al. Recipient cytotoxic T lymphocyte antigen-4 +49 G/G genotype is associated with reduced incidence of hepatitis B virus recurrence after liver transplantation among Chinese patients[J]. Liver Int, 2007, 27(9):1202-1208. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=470f553a1726f1d52eb519137ec169e6
    [29]
    XIA C, LU M, ZHANG Z, et al. TLRs antiviral effect on hepatitis B virus in HepG2 cells[J]. J Appl Microbiol, 2008, 105(5):1720-1727. DOI: 10.1111/j.1365-2672.2008. 03896.x.
    [30]
    JIANG M, BROERING R, TRIPPLER M, et al. Toll-like receptor-mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen[J]. J Viral Hepat, 2014, 21(12):860-872. DOI: 10.1111/jvh.12216.
    [31]
    TESTONI B, LEVRERO M, ZOULIM F. Challenges to a cure for HBV infection[J]. Semin Liver Dis, 2017, 37(3):231-242. DOI: 10.1055/s-0037-1606212.
    [32]
    SUNG WK, ZHENG H, LI S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma[J]. Nat Genet, 2012, 44(7):765-769. DOI: 10.1038/ng.2295.
    [33]
    CHAUHAN R, CHURCHILL ND, MULROONEY-COUSINS PM, et al. Initial sites of hepadnavirus integration into host genome in human hepatocytes and in the woodchuck model of hepatitis B-associated hepatocellular carcinoma[J]. Oncogenesis, 2017, 6(4):e317. DOI: 10.1038/oncsis.2017.22.
    [34]
    COUGOT D, NEUVEUT C, BUENDIA MA. HBV induced carcinogenesis[J]. J Clin Virol, 2005, 34 (Suppl 1):S75-S78. http://d.old.wanfangdata.com.cn/Periodical/gxykdx200102001
    [35]
    MARUSAWA H, UEMOTO S, HIJIKATA M, et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen[J]. Hepatology, 2000, 31(2):488-495. doi: 10.1002/hep.510310232
    [36]
    XUAN SY, SUN Y, ZHANG J. The influence to the function of cellular immunity after being infected by HBV in the PBMC in chronic hepatitis B[J]. Chin J Epidemiol, 1997, 18(2):80-82. http://cn.bing.com/academic/profile?id=46a636ad47400a355ec33ff5657947b0&encoded=0&v=paper_preview&mkt=zh-cn
    [37]
    COFFIN CS, MULROONEY-COUSINS PM, PETERS MG, et al. Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy[J]. J Viral Hepat, 2011, 18(6):415-423. DOI: 10.1111/j.1365-2893.2010.01321.x.
    [38]
    BUDZINSKA MA, SHACKEL NA, URBAN S, et al. Cellular genomic sites of hepatitis B virus DNA integration[J]. Genes (Basel), 2018, 9(7):365. DOI: 10.3390/genes9070365.
    [39]
    GATTA A, GIANNINI C, LAMPERTICO P, et al. Hepatotropic viruses: new insights in pathogenesis and treatment[J]. Clin Exp Rheumatol, 2008, 26(1 Suppl 48): S33-S38. http://cn.bing.com/academic/profile?id=b2074f0be7c58145999b2f850f792fd2&encoded=0&v=paper_preview&mkt=zh-cn
    [40]
    VLACHOGIANNAKOS J, PAPATHEODORIDIS GV. Hepatitis B: who and when to treat?[J]. Liver Int, 2018, 38 (Suppl 1):71-78. DOI: 10.1111/liv.13631.
    [41]
    HUANG W, ZHAO F, HUANG Y, et al. Rapamycin enhances HBV production by inducing cellular autophagy[J]. Hepat Mon, 2014, 14(10):e20719. DOI: 10.5812/hepatmon.20719.
    [42]
    BRENNAN DC, AGUADO JM, POTENA L, et al. Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms[J]. Rev Med Virol, 2013, 23(2):97-125. DOI: 10.1002/rmv.1733.
    [43]
    于乐成, 范晔, 李平等.与直接抗病毒药物应用相关的HCV/HBV双重感染的特点及其诊治管理[J].临床肝胆病杂志, 2018, 34(2):238-241. DOI: 10.3969/j.issn.1001-5256.2018.02.004.

    YU LC, FAN Y, LI P, et al. Features and management of patients with hepatitis C virus/hepatitis B virus dual infection associated with the application of direct-acting antiviral agents[J]. J Clin Hepatol, 2018, 34(2):238-241. DOI: 10.3969/j.issn.1001-5256.2018.02.004.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (128) PDF downloads(11) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return